Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Search Results

Your search returned 1870 record(s).

Page 89 of 187  |  Previous Page   |  Next Page

Cancer Type:   Sort By:

This Search was Made Possible by:

  Survival: Patients: Toxicity: Treatment: Hospital: Country: Date:
881 12.7 months GBM Chemotherapy
University Hospital Lausanne Switzerland 3/2005
Treatment Details: Patients: This trial involved 206 patients with glioblastoma. Demographic information on the patients was not reported. The patients were randomly divided into two groups. In addition, al
882 12.7 months MPM 4 Chemotherapy
C. Forlanini Hospital Italy 1/2005
Treatment Details: Patients: This Phase II study involved 28 patients with mesothelioma, of whom 26 were evaluated. Twenty-two patients were men, and six were women. The median age was 63 years. Twenty-two
883 12.7 months Locally advanced NSCLC 5 Chemotherapy
University of Pittsburgh Cancer Institute United States 9/2005
Treatment Details: Patients: This Phase II/III study involved 276 patients with advanced non-small-cell lung cancer who were randomly assigned into three groups. Group B had 74 patients (54 men, 20 women); tw
884 12.7 months Malignant Pleural Mesothelioma 4 Chemotherapy
Istituto Clinico Humanitas Italy 3/2006
Treatment Details: Patients: This phase II study involved 102 patients with malignant pleural mesothelioma that were not candidates for curative surgery. The median patient age was 65, ranging from 38 to 79.
885 12.7 months metastatic breast cancer 4 Chemotherapy
Centre Paul Strauss France 3/2006
Treatment Details: Patients: This Phase II study included forty-two patients with metatistic breast cancer who previously received at least one taxane-based regimen and/or an anthracycline regimen. The media
886 12.7 months Metastatic, castration-resistant prostate cancer 5 Chemotherapy
Royal Marsden NHS Foundation Trust and The Institute of Cancer Research United Kingdom 10/2010
Treatment Details: Patients: This phase 3 study involved men with metastatic castration-resistant prostate cancer. Patients were separated into two treatment groups. Group A consisted of 377 men with a medi
887 12.7 months Castration-resistant prostate cancer 4 Chemotherapy
University Federico II Italy 3/2011
Treatment Details: Patients: This phase II study involved 25 male patients with castration-resistant prostate cancer who had previously been treated with docetaxel. The median patient age was 65 years. Tr
888 12.6 months Advanced hepatocellular carcinoma 3 Biologic therapy
The Ohio State University Comprehensive Cancer Center United States 9/2009
Treatment Details: Patients: This study involved 26 patients with advanced hepatocellular carcinoma. The median age of the group was 58 years and 18 were male. Treatment: Patients were treated with the b
889 12.6 months Recurrent or persistant ovarian/fallopian tube/or primary peritoneal cancer 4 Chemotherapy
University of Washington School of Medicine United States 8/2008
Treatment Details: Patients: This phase II study involved 23 women with recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer. The median age was 58, ranging from 43
890 12.6 months GBM 5 Biologic therapy
Dana-Farber/Brigham and Women's Cancer Center United States 4/2008
Treatment Details: Patients: This phase II study involved fifty patients with newly diagnosed glioblastoma. There were 18 women and 32 men; their median age was 54, ranging from 29-78 years of age. Treatm
Page 89 of 187  | Previous Page  | Next Page